“We've got a read out of our trial, against NOAC. That'll be in 2027.”

In context

“of the KOLs that are working on the trial, Really making sure that we understand of how how and how good this next generation is. I think that's gonna allow us to do that. We've actually completed the enrollment of that trial, so we're gonna be filing you know, we've to do the follow-up and then we'll be filing in the first half of the next year. So we'll see if, if this is a, if this is a 2026 launch or if it's more of 2027 launch. But I think that's gonna be hugely important. And I think it's gonna be hugely important as it relates to our full portfolio here. We think that it's going to be a differentiator for us. To be able to have not all not only all the PFA tools and mapping tools and service and support, but now to be able to add a a a much more competitive device on the LAA side. We've got a read out of our trial, against NOAC. That'll be in 2027. I I understand that there'll be a readout from competitive system next year, but I think that this is a this is a high growth area and one that's got a lot of attention, from me. And from the management of our device teams on how we can kind of leverage, the portfolio better. So, I've got high expectations as we go into as we go into year and especially with the next generation product. Danielle Antalffy: Gotcha. And then just the quick question on diabetes. You know, we've talked in the past about CGM becoming standard of care. And I'll be very honest. It it surprises me that we're still only 20% penetrated in The U. S. In basal. What do you think are still the barriers to this, and how how long will they persist? I mean, you talk to clinicians, and it feels like the momentum is there, a”